AMORCYTE
Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR–001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effe... ct. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and other services for the cell therapy industry, to provide Amorcyte with a pharmaceutical grade cGMP manufactured product that can be distributed commercially. Amorcyte was founded by Andrew Pecora, M.D., Chairman of The John Theurer Cancer Center at Hackensack University Cancer Center, with initial investment by Novitas Capital and Colt Ventures.
AMORCYTE
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2005-01-01
Address:
Allendale, New Jersey, United States
Country:
United States
Website Url:
http://www.amorcyte.com
Total Employee:
1+
Status:
Active
Contact:
908-510-0617
Email Addresses:
[email protected]
Total Funding:
1.03 M USD
Technology used in webpage:
Domain Not Resolving
Similar Organizations
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.amorcyte.com
- Host name: frault5.hostarmada.net
- IP address: 172.104.152.18
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Amorcyte"
Amorcyte Company Profile 2024: Valuation, Investors, Acquisition ...
Amorcyte General Information Description. Developer of cell therapy products to treat cardiovascular diseases. The company's products include AMR-001, a bone marrow derived …See details»
Amorcyte Inc - Company Profile and News - Bloomberg Markets
Company profile page for Amorcyte Inc including stock price, company news, executives, board members, and contact informationSee details»
Amorcyte - Contacts, Employees, Board Members, Advisors
Amorcyte is a biotechnology company developing cell therapy products to treat cardiovascular disease.See details»
Amorcyte - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jul 21, 2011: Debt Financing - …See details»
NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular …
Oct 17, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based …See details»
Amorcyte, a NeoStem Company, Announces Expansion of …
Jan 10, 2012 Amorcyte, Inc. (“Amorcyte”), a NeoStem, Inc. company (NYSE Amex: NBS) (“NeoStem” or the “Company”), today announced the expansion of intellectual property …See details»
NeoStem acquires Amorcyte, a clinical stage ... - Cardiovascular …
Oct 25, 2011 NeoStem, intends to initiate, no later than the first quarter of 2012, a phase II clinical trial for Amorcyte’s lead product candidate, AMR-001, for the treatment of acute …See details»
NeoStem Signs Definitive Merger Agreement To Acquire …
Jul 18, 2011 NeoStem, Inc.("NeoStem" or the "Company"), an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will …See details»
NeoStem to Acquire Cell Therapies Firm Amorcyte for Clinical …
Jul 15, 2011 NeoStem is acquiring Amorcyte in a shares-based deal that has already been agreed to by holders of more than 50% of the latter’s shares. Amorcyte is a cell therapy …See details»
Lisata Therapeutics acquires Amorcyte - 2011-07-14 - Crunchbase
Acquired Organization: Amorcyte Amorcyte is a biotechnology company developing cell therapy products to treat cardiovascular disease. Acquiring Organization: Lisata Therapeutics Lisata …See details»
Amorcyte Stem Cell Therapy Demonstrates Clinically Significant ...
Dec 21, 2010 Amorcyte's therapy aims to limit ventricular remodeling. About Amorcyte, Inc. Amorcyte is a privately held biotechnology company developing cell therapy products to treat …See details»
Amorcyte Granted Landmark Patent - PR Newswire
Sep 13, 2010 /PRNewswire/ -- Amorcyte, Inc. (Amorcyte), a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that...See details»
Amorcyte Cardiac Cell Therapy Trial Passes First Stage and Opens …
Jan 9, 2007 Amorcyte, Inc. , a biotechnology company developing cell therapy products to treat cardiovascular disease has announced that its phase I clinical trial is now open in two new …See details»
NeoStem, Inc. Signs Definitive Merger Agreement to Acquire …
Jul 15, 2011 Amorcyte's lead product candidate, AMR-001, is ready to initiate a Phase II study for the treatment of acute myocardial infarction (AMI). Of the approximately 800,000 …See details»
Amorcyte - Crunchbase
Amorcyte is a biotechnology company developing cell therapy products to treat cardiovascular disease.See details»
Stem Cell Therapy Demonstrates Clinically Significant Reperfusion …
Dec 22, 2010 “This publication further demonstrates the potential importance AMR-001 may have on the treatment of heart attack patients,” said Andrew Pecora, M.D., Amorcyte Founder …See details»
Amorcyte Granted Key Patent for Stem Cell Therapy to Prevent …
Sep 16, 2010 U.S. patent is first in industry to fully enable practical development of stem cell therapies for treating heart damage following a heart attack.See details»
Amorcyte - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Amorcyte . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 13. About. Amorcyte is …See details»
Amorcyte Completes Phase I Trial of Stem Cell Therapy for Acute ...
Apr 2, 2008 Amorcyte lead product, AMR-001, is an autologous stem cell product for the treatment of damaged heart muscle following AMI.See details»